Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo transdermal Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

NCT02876900
View directory record Official record
Conditions
Schizophrenia
Interventions
Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch, Placebo
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

NCT00032929
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
16
States / cities
Tucson, Arizona • Berkeley, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI

NCT04671030
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate, Iontophoresis
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 24, 2026, 1:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME

NCT02174718
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Transdermal D Patch, Oral vitamin D3, Placebo patch, Oral placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion

NCT03248440
View directory record Official record
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
6 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
65
States / cities
Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 24, 2026, 1:59 AM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494
View directory record Official record
Conditions
Moderate to Severe Acute Lower Back Pain
Interventions
SP-103, Placebo
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Fernandina Beach, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 1:59 AM EDT
Recruiting Phase 4 Interventional

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277
View directory record Official record
Conditions
Depression, Psychosis, Anhedonia
Interventions
Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3

NCT00390559
View directory record Official record
Conditions
Drug Addiction, Smoking Cessation
Interventions
Nicotine transdermal system, Nicotine containing cigarette, Placebo cigarette
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

NCT03397862
View directory record Official record
Conditions
Skin Irritation, Sensitization
Interventions
Donepezil TDS, Vehicle TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 24, 2026, 1:59 AM EDT
Terminated Phase 4 Interventional Results available

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

NCT02365870
View directory record Official record
Conditions
Anxiety Disorders, Parkinson Disease
Interventions
rotigotine transdermal patch, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

NCT00466791
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms

NCT01389102
View directory record Official record
Conditions
Hot Flashes
Interventions
Estradiol transdermal one 90 μL spray, Estradiol transdermal spray, two 90 μL sprays, Estradiol transdermal three 90 μL sprays, Placebo transdermal two 90 μL sprays, Placebo transdermal three 90 μL sprays, Placebo transdermal one 90 μL spray
Drug
Lead sponsor
Lumara Health, Inc.
Industry
Eligibility
35 Years and older · Female only
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Oro Valley, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Obesity in Women Via Estradiol Regulation

NCT00687739
View directory record Official record
Conditions
Obesity
Interventions
leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 24, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional

Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty

NCT05412992
View directory record Official record
Conditions
Pain, Postoperative
Interventions
DMTS Patch, Placebo Patch
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Hormone and Information Processing Study

NCT00539305
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 90 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Sep 24, 2026, 1:59 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy

NCT01345448
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine, Placebo Lotion
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Sep 24, 2026, 1:59 AM EDT
Recruiting Phase 2 Interventional

Transdermal Estrogen in Women With Anorexia Nervosa

NCT03875378
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Transdermal estrogen, Placebos
Drug
Lead sponsor
Pouneh K. Fazeli, MD
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

NCT00108771
View directory record Official record
Conditions
Pain
Interventions
ZR-02-01 Fentanyl Transdermal Matrix Patch, Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 24, 2026, 1:59 AM EDT
Withdrawn Phase 2 Interventional

Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure

NCT00370019
View directory record Official record
Conditions
Premature Ovarian Failure
Interventions
Estradiol/Medroxyprogesterone acetate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 24, 2026, 1:59 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331214
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 24, 2026, 1:59 AM EDT